Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ketek Labeling Gets Updated Warning, But Not Format, After Liver Toxicity

Executive Summary

Sanofi-Aventis is making a relatively modest labeling change to its antibiotic Ketek (telithromycin) following reports of hepatoxicity

You may also be interested in...



FDA Panel Supports Ketek as Second-Line for CAP; Suggests Black Box

Sanofi-Aventis' Ketek should not be the first-line treatment for community acquired pneumonia, members of an FDA advisory panel cautioned when they recommended continued marketing of the antibiotic for CAP

FDA Panel Supports Ketek as Second-Line for CAP; Suggests Black Box

Sanofi-Aventis' Ketek should not be the first-line treatment for community acquired pneumonia, members of an FDA advisory panel cautioned when they recommended continued marketing of the antibiotic for CAP

Two Strikes For Ketek: Cmtes. Want Bronchitis, Sinusitis Indications Rescinded

FDA's Anti-Infective Drug and Drug Safety and Risk Management Advisory Committees are recommending stripping Sanofi-Aventis' Ketek of its bronchitis and sinusitis indications

Related Content

UsernamePublicRestriction

Register

PS047342

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel